Journal article
Rofecoxib does not appear to increase the risk of venous thromboembolism: A systematic review of the literature
Abstract
BACKGROUND AND OBJECTIVE: Rofecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, has been associated with increased arterial thrombosis. It is unknown whether (COX-2) inhibition is associated with venous thromboembolism (VTE).We investigated, using a systematic review of the literature, the association between rofecoxib and venous thrombosis.
METHODS: A search strategy was developed and implemented to identify all English language studies …
Authors
Goy J; Paikin J; Crowther M
Journal
Thrombosis Research, Vol. 134, No. 5, pp. 997–1003
Publisher
Elsevier
Publication Date
November 2014
DOI
10.1016/j.thromres.2014.08.030
ISSN
0049-3848